Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression: a Randomized Controlled Trial


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03027362

Organisation Name: Yale University

Overal Status: Completed

Start Date: January 2017

Last Update: February 5, 2020

Lead Sponsor: Yale University

Brief Summary: The goals of this study are: 1) to investigate the efficacy of combining ketamine with intensive cognitive behavioral therapy (CBT) to sustain the antidepressant effects of ketamine; and 2) to determine ketamine's delayed effects on learning and memory, and to explore the relationship between any ketamine-induced changes in learning and memory and duration of antidepressant efficacy, with and without CBT augmentation. Subjects with a diagnosis of MDD who are treatment-resistant to at least 2 antidepressants and have chosen to pursue clinical ketamine treatment at Yale Psychiatric Hospital will be recruited for the study.

Conditions:
  • Depressive Disorder, Major


Total execution time in seconds: 0.20082211494446